Back to Home
Multimedia

Burst CME™: Tackling Adverse Events With Targeted Therapies for Diffuse B-Cell Lymphoma

Release Date

September 30, 2024

Expiration Date

October 1, 2025

Credits

0.5 CME

Specialties

General Oncology

Release Date: September 30, 2024

Expiration Date: September 30, 2025

Activity Overview

Along the treatment continuum for patients with DLBCL, numerous decisions regarding treatment need to be made to ensure optimal outcomes. This also necessitates knowledge of the adverse events associated with each approach. In this educational activity, experts in the management of DLBCL discuss treatment options and their associated safety profiles, with practical advice on the best approaches for different toxicities that may jeopardize the success of therapy.

Target Audience

This online educational activity is primarily directed toward academic and community hematologists, oncologists, oncology nurses, oncology advanced practice providers, oncology pharmacists, and other health care providers involved in the diagnosis and management of patients with DLBCL.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Recognize adverse events associated with the different classes of targeted therapies used in R/R DLBCL
  • Formulate strategies for the monitoring, identification, and mitigation of toxicities linked to targeted agents in patients with DLBCL
Burst CME™: Tackling Adverse Events With Targeted Therapies for Diffuse B-Cell Lymphoma

GET STARTED WITH THIS PROGRAM:

Register now to gain access to this program.

Create AccountAlready Registered? Login Here

Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource, LLC, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit.™ Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Pfizer, Inc.

Course

Burst CME™: Tackling Adverse Events With Targeted Therapies for Diffuse B-Cell Lymphoma

Create Account